A method for lipoprotein (a) Isolation from a small volume of plasma with applications for clinical research

References

Page 1

	Year	Citations
The PRIDE database and related tools and resources in 2019: improving support for quantification data Yasset Pérez‐Riverol, Attila Csordás, Jingwen Bai, Nucleic Acids Research EngineeringGeneticsBiological Mass SpectrometryMolecular BiologyGenomics	2018	7.2K
Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis Amit Khera, Marina Cuchel, Margarita de la Llera-Moya, New England Journal of Medicine	2011	1.9K
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen John W. McLean, James Tomlinson, Wun-Jing Kuang, Nature Protein FunctionHuman ApolipoproteinNatural SciencesGeneticsBiochemical Genetics	1987	1.9K
HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events Anand Rohatgi, Amit Khera, Jarett D. Berry, New England Journal of Medicine	2014	1.4K
ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins Nan Wang, Debin Lan, Wengen Chen, Proceedings of the National Academy of Sciences Proteinlipid InteractionMolecular BiologyPlasma HdlLipid MovementCellular Physiology	2004	1.1K
Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. Eric Boerwinkle, C C Leffert, Jimmy Lin, Journal of Clinical Investigation GeneticsGenetic EpidemiologyHuman PolymorphismHyperlipidemiaPlasma Lp	1992	961
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease Sotirios Tsimikas, Ewa Karwatowska‐Prokopczuk, Ioanna Gouni‐Berthold, New England Journal of Medicine	2020	924
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Michelle L. O’Donoghue, Sergio Fazio, Robert P. Giugliano, Circulation	2019	895
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials Nicholas J. Viney, Julian C. van Capelleveen, Richard S. Geary, The Lancet Dose-ranging TrialsPharmacologyHyperlipidemiaPharmacotherapyDyslipidemia	2016	730
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study Sotirios Tsimikas, Nicholas J. Viney, Steven G. Hughes, The Lancet Lipid DisorderPharmacologyTherapeutic EfficacyHyperlipidemiaAntisense Therapy	2015	460

Page 1